~~<i id='DAB5E7A997'><strike id='DAB5E7A997'><tt id='DAB5E7A997'><pre id='DAB5E7A997'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

explore

author：explore 2025-10-02 19:20:12 - browse：83519

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Abortion clinic in Cancun will cater to Americans

explore

hotspot

entertainment

leisure time

focus

explore

Journalist,poet,andteacherMeghanO’Rourkeonstageatthe2023STATSummit.STATWhenherlifewasupturnedbyanacc

WSS

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: Meghan O’Rourke on making chronic illness visible

The Sacklers, horror, and ‘The Fall of the House of Usher’

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Wikipedia

explore

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Extreme heat events are a public health emergency

Virginia high school admissions case could be legal follow

Removing probiotics from the NICU could threaten preemies' health

How one medical school became remarkably diverse

UCSF medical school apologizes for unethical prisoner experiments

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: Ending the crisis of Black deaths in the U.S.

hotspot

Removing probiotics from the NICU could threaten preemies' health

Roivant's CEO is a star, but biotech's black hole persists

Free speech concerns arise in wake of journal editor Eisen's firing

Free speech concerns arise in wake of journal editor Eisen's firing

HPV cancer vaccine study demonstrates efficacy

Excited delirium, Elijah McClain, and emergency physicians

entertainment

leisure time

focus

explore